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Available online xxxxBackground: Glioblastoma (GBM) is the most frequent and malignant primary brain tumor in adults and despite
the progress in surgical procedures and therapy options, the overall survival remains very poor. Glutamate and
α-KG are fundamental elements necessary to support the growth and proliferation of GBM cells. Glutamate ox-
idative deamination, catalyzed by GLUD2, is the predominant pathway for the production of α-KG.
Methods: GLUD2 emerged from the RNA-seq analysis of 13 GBM patients, performed in our laboratory and a mi-
croarray analysis of 77 high-grade gliomas available on the Geo database. Thereafter, we investigated GLUD2 rel-
evance in cancer cell behavior by GLUD2 overexpression and silencing in two different human GBM cell lines.
Finally, we overexpressed GLUD2 in-vivo by using zebraﬁsh embryos and monitored the developing central ner-
vous system.
Findings:GLUD2 expressionwas found associated to the histopathological classiﬁcation, prognosis and survival of
GBM patients. Moreover, through in-vitro functional studies, we showed that differences in GLUD2 expression
level affected cell proliferation, migration, invasion, colony formation abilities, cell cycle phases, mitochondrial
function and ROS production. In support of these ﬁndings, we also demonstrated, with in-vivo studies, that
GLUD2 overexpression affects glial cell proliferation without affecting neuronal development in zebraﬁsh em-
bryos.
Interpretation:We concluded that GLUD2 overexpression inhibited GBM cell growth suggesting a novel potential
drug target for control of GBM progression. The possibility to enhance GLUD2 activity in GBM could result in a
blocked/reduced proliferation of GBM cells without affecting the survival of the surrounding neurons.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Zebraﬁsh1. Introduction
Glioblastoma (GBM, World Health Organization grade IV) is the
most common malignant primary brain tumor, characterized by an ex-
tremely aggressive clinical phenotype due to inter- and intra-patient
genomic and histopathological diversity, diffuse inﬁltrative growth, in-
tense vascularization and innate treatment resistance [1–6]. Despite sig-
niﬁcant advances in both neurosurgical techniques and medical
therapy, GBM treatment remains difﬁcult, as present-days therapieschi), michela.ori@unipi.it
. This is an open access article under
itochondrial enzyme GLUD2are not curative and the latest improvements in radio-chemotherapy
have been reported by Stupp et al. [7] N10 years ago [2,8].
GBM prognosis is extremely poor with a median overall survival be-
tween 12 and 15 months and a 5-year survival rate of b5%, making this
survival rate one of theworst observed inmodern-day oncology [1,2,5].
Almost all patients, under current standard therapy, includingmaximal
safe surgical resection followed by radiotherapy and temozolomide che-
motherapy, will develop recurrent diseases with progressive neurolog-
ical deﬁcits and inevitable death. Second surgery is an applicable
therapy option in limited cases; however, an increased risk of neurolog-
ical morbidity often limits this secondary resection [9].
Unlike in other tumors, where in the past 50 years, the prognosis and
life expectancy have strongly increased due to intensive research efforts
into tumor cell biology, in GBM, such investigations, have raised more
doubts than they have solved [3]. Therefore, there is still an urgentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
The involvement of GLUD2 in glioma metabolism and growth has
already been suggested, but only in the presence of IDH1 muta-
tions (Cancer Res, 2018 and Proc Natl Acad Sci U S A, 2014). It
has been described that GLUD1 and GLUD2 are overexpressed
in IDH1 mutant tumors. In this context, the expression of
GLUD2 makes cells resistant to the inhibitory effects of growth
of the IDH1R132H mutation, by providing a-KG to feed the citric
acid cycle and support the synthesis of lipids. In other studies, in-
stead, it was investigated the inhibition of glutamate dehydroge-
nase activity in glioma, without distinguishing the two existing
isoforms GLUD1 and GLUD2 (Cancer Res, 2009). To the best of
our knowledge, this is the first work where GLUD2 is investigated
as a key player in GBM progression. The research in PubMed data-
base, according to the terms “GLUD2” or “GDH2” and “glioblas-
toma”, does not provide any other results except for the work,
previously mentioned, that was published on Proc Natl Acad Sci
U S A in 2014.
Added value of this study
In this studywe found an association of GLUD2mRNAexpression
levels to the prognosis and survival of patients with GBM. There-
after, through in-vitro functional studies using human GBM cell
lines and in-vivo studies in zebrafish model, we investigated the
importance of GLUD2 regulation in cell behavior, metabolism
and development. GLUD2 expression was related to the histo-
pathological classification, prognosis and survival of patients
with GBM. Moreover, differences in GLUD2 expression level af-
fected cell proliferation,migration, invasion, colony formation abil-
ities, cell cycle phases, mitochondrial function and ROS
production. In support of these findings, we also demonstrated
that GLUD2 overexpression decreases glial cell proliferation with-
out affecting neurons development in zebrafish embryos.
Implications of all the available evidence
The possibility to enhanceGLUD2 activity in GBM could result in a
blocked/reduced proliferation of GBM cells without affecting the
survival of the surrounding neurons. To the best of our knowl-
edge, this is the first work where GLUD2 is considered the key
player in GBM progression. These observations may provide a
new target for therapeutic interventions in GBM to reduce tumor
progression and aggressiveness.
2 S. Franceschi et al. / EBioMedicine xxx (xxxx) xxx–xxxneed for novel and effective therapeutic strategies for treating these tu-
mors and ultimately improve GBM patients' chances of survival.
One of the emerging hallmarks of cancer is the deregulation of cellu-
lar energetics and the most signiﬁcant reprogramming occurs in the
metabolic machinery in GBM [1,10,11]. Thus, cancer cell metabolism is
now a ﬁeld of intensive investigation to discover new valuable thera-
peutic targets and biomarkers [10]. In particular, it is well known that
glutamine metabolism plays key roles in cellular growth and invasion,
supporting tumor progression and poor patient outcomes [12]. The ini-
tial step in glutamine degradation involves its conversion into gluta-
mate catalyzed by glutaminase and the conversion of glutamate into
α-ketoglutarate (α-KG), by glutamate dehydrogenase. Especially in
tumor hypoxia condition, glutamate and α-KG are fundamental ele-
ments in glutaminolysis and reductive carboxylation, needed to sustain
cancer cell growth and proliferation. Moreover, glutamate release canPlease cite this article as: Franceschi S, et al, Mitochondrial enzyme GLUD2
https://doi.org/10.1016/j.ebiom.2018.10.008affect nearby cells, since high glutamate levels induce astrocyte swelling
and apoptosis, favoring tumor expansion [13]. Furthermore, an efﬁcient
excitatory amino acids clearance from astrocytes is essential in order to
maintain low extracellular glutamate concentrations and guarantee an
adequate regulation of synaptic transmission and prevents glutamate
neurotoxicity [14].
Glutamate dehydrogenase 2 (GLUD2) catalyzes the reversible inter-
conversion of glutamate to α-KG and ammonia while reducing NAD(P)
+ to NAD(P)H as cofactors. This enzyme plays a key role in cellular ho-
meostasis, being at the interface between amino acid and carbohydrate
metabolism. GLUD2 is linked to important cellular processes including
Krebs cycle, ammonia control and energy generation [15,16].
In this study, we investigated the correlation of GLUD2 expression to
patients' prognosis and survival. We investigated, through in-vitro and
in-vivo functional studies, how an alteration of GLUD2 expression
could affect the behavior of human glioblastoma cells. Furthermore,
we evaluated the effect of GLUD2 expression on the behavior of neurons
and glial cells in the zebraﬁsh developing brain.
2. Materials and methods
2.1. Transcriptome analysis
NGS and microarray analysis data were obtained from our previous
paper [17] and the Gene Expression Omnibus (GEO) GSE4271 dataset
[18] respectively, together with molecular and clinical information. In
particular, NGS analysis was performed on FFPE tumor tissues from 13
primary human GBM subjects selected from the archives of the Anat-
omy Pathology Institute of the University of Pisa, Italy. Subjects were
chosen by the same pathologist, they have same histology, similar con-
dition and treatment and were grouped depending on time of recur-
rence free survival (RFS) after ﬁrst surgery: 6 Short (S) b6 months, 3
Medium (M) between 16 and 23 months and 4 Long (L) over
25 months. NGS data were analyzed and visualized with Partek Flow
software (Partek, Inc., St. Louis, MO, USA). Microarray GSE4271 proﬁle
was downloaded from GEO database (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE4271). GSE4271 contains the mRNA proﬁle
of 77 primary grade III and IV astrocytomas characterized by molecular
class (proneural, proliferative and mesenchymal) [18] and overall
survival.
2.2. Immunohistochemistry
2.2.1. Immunohistochemistry performed on FFPE GBM tissues
Sections of 5 μm thickness were deparafﬁnized in xylene and
rehydrated in graded alcohols. Immunohistochemistry was performed
using the Mouse speciﬁc HRP/DAB (ABC) Detection IHC Kit (Abcam,
Cambridge, UK) according to manufacturer's protocol. The antigen
unmasking was achieved with MS-unmasker solution (DIAPATH,
Martinengo, BG, Italy) in microwave. GLUD2 primary antibody (cat.
number SAB1400112, Sigma Aldrich, St Louis, MO) was used at 1:150
dilution for 1 h at room temperature. Slideswere developedwith diami-
nobenzidine chromogen (DAB) (DAKO, Glostrup, DK) and counter-
stained with hematoxylin. Negative controls included the omission of
the primary antibody. Slides were analyzed using the inverted micro-
scope CARL ZEISS Axio Observer Z1FLMot, and images were taken
with CARL ZEISS AXIOCAM Icc1 camera (Zeiss, Oberkochen, Germany).
2.2.2. Immunohistochemistry performed on embryos
Immunohistochemistry was performed following standard proce-
dures. Embryos were blocked in 20% lamb serum and incubated with
mouse GLUD2 antibody (1:250 dilution, cat. number SAB1400112,
Sigma Aldrich), mouse HuC/D antibody (1:500, cat. number A-21271,
Invitrogen), or rabbit phospho-histoneH3 antibody (1:500, cat. number
06–570, Millipore). Horseradish peroxidase-conjugated secondary anti-
bodies goat anti-mouse (1:500, cat. number G21040, Invitrogen), orplays a critical role in glioblastoma progression, EBioMedicine (2018),
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detect primary antibodies, and DAB (Roche) was used as a substrate
for peroxidase. Images of embryos were acquired using a stereomicro-
scope (SMZ1500, Nikon) equipped with digital camera with LAS Leica
Imaging software (Leica, Wetzlar, Germany). Images were processed
using Adobe Photoshop software (Adobe System Incorporated, San
Josè, CA, USA). The same magniﬁcation was always maintained within
each control and GLUD2-injected image pair.
2.3. Cell lines and transfection
T98G and U118 GBM cell lines were obtained from American Type
Culture Collection (ATCC, Rockville, MD). To ensure the quality and in-
tegrity of human cell lines, cells from the initial thawed vials were
used for up to a maximum of 10 passages in all the experiments, as rec-
ommended by the supplier. T98G and U118 were grown asmonolayers
in Dulbecco's Modiﬁed Eagle Medium (DMEM) low glucose and high
glucose respectively, supplemented with 10% FBS and 1% Penicillin-
Streptomycin. Cells were tested for the presence of mycoplasma (EZ-
PCR Mycoplasma Test Kit; Biological Industries, Beth Haemek, Israel)
with negative results. Ampliﬁcation of GLUD2 gene was performed by
PCR with the 5′ end primer (5′-TAActcgagGACCCTTCCTTCCTAGTCGC-
3′) containing XhoI-site and with the 3′ end primer (5′-CGggatccTCAG
CCATGATCCATCTATGTGA-3′) containing BamHI-site. PCR product was
subcloned into pIRES2-AcGFP vector (Clontech Laboratories, Mountain
View, CA, USA). GLUD2 sequence was conﬁrmed by Sanger sequencing.
Plasmid transfection was performed with Lipofectamine 3000 Reagent,
following manufacturer's instructions. GLUD2 was silenced using
GLUD2 siRNA Silencer Select (Thermo Fisher Scientiﬁc) and the Silencer
Select Negative Control No. 1 siRNAwas used as non-targeting negative
control siRNA (Thermo Fisher Scientiﬁc). SiRNA transfection was per-
formed with Lipofectamine RNAiMAX Reagent (Thermo Fisher Scien-
tiﬁc) following manufacturer's instructions. Cells were incubated for
48 h after GLUD2 overexpression/silencing prior to characterization
and functional experiments.
2.4. Quantitative real-time PCR
2.4.1. Cell lines mRNA expression analysis
Total cellular RNA was extracted from GBM cells using the Maxwell
16 LEV simplyRNA kit (Madison, WI) according to the manufacturer's
instructions, and quantitated using a Qubit 2.0 Fluorometer (Thermo
Fisher Scientiﬁc, Waltham, MA). Total RNA was reverse transcribed
into cDNA using the RT-NanoScript kit (PrimerDesign, Southampton,
UK). Real Time PCR was performed following the manufacturer's in-
struction of the SsoAdvanced SYBRGreen Supermix kit (Bio-Rad, Hercu-
les, CA) on CFX96 instrument (Bio-Rad). TBP expression values were
used for normalization. The following primers were used: GLUD2, 5′-
CACTCTGCCTTGGCATACAC-3′ and 5′-CTCAGGTCCAATCCCAGGTT-3′,
TBP, 5′-AGTTCTGGGATTGTACCGCA-3′, 5′-TTATATTCGGCGTTTCGGGC-
3′, Cyclin E, 5′-TTCTTGAGCAACACCCTCTTCTGCAGCC-3′ and 5′-TCGCCA
TATACCGGTCAAAGAAATCTTGTGCC-3′, Cyclin D1, 5′-ACAAACAGATC
ATCCGCAAACAC-3′, 5′-TGTTGGGGCTCCTCAGGTTC-3′. Gene expression
analysis was performed using CFX Manager Software (Bio-Rad). All ex-
pression experiments were performed in triplicate.
2.4.2. Embryos mRNA expression analysis
Total RNA was extracted from zebraﬁsh embryos (30 per experi-
mental group) using Nucleospin® RNA (Macherey-Nagel) according
to manufacturer's instructions. cDNA was synthesized from total RNA
using iScript™ cDNA Synthesis Kit (Bio-Rad) and quantitative real-
time PCR was performed following the manufacturer's protocol of
GoTaq® qPCR master mix (Promega). Ct values were obtained for
each gene and normalized to β-actin. Fold change was calculated rela-
tive to control embryos expression level using the 2-ΔΔCt method. The
following primers were used: pcna (F: 5′-TCGGGTGAGTTTGCCCGCAPlease cite this article as: Franceschi S, et al, Mitochondrial enzyme GLUD2
https://doi.org/10.1016/j.ebiom.2018.10.008TC-3′; R: 5′-GCCCAGCTCTCCGCTGGCAGA-3′), cyclin D1 (F: 5′-CTGCGC
AAACACGCCCAGAC-3′; R: 5′-TACCGCTGCAGCAACACTGCC-3′), gfap (F:
5′-GCAGACAGGTGGATGGACTCA-3′; R: 5′-GGCCAAGTTGTCTCTCTCG
ATC-3′), β-actin (F: 5′-CGAGCAGGAGATGGGAACC-3′; R: 5′-CAACGG
AAACGCTCATTGCC-3′).
2.5. Western blot
For each samples 40 μg of proteins were loaded on the 10% Mini-
PROTEAN TGX Gel (Bio-Rad). Proteins were transferred from gels to
membrane with Trans-Blot Turbo transfer system (Bio-Rad). GLUD2
and β-tubulin primary antibodies (HPA043640, Sigma Aldrich) were
used at 1:250 and 1:200 dilution respectively. Secondary antibodies
Goat Anti-Mouse IgG H&L (HRP) (ab6789, Abcam, Cambridge, UK)
and Goat Anti-Rabbit IgG H&L (HRP) (ab6721, Abcam) were used at a
dilution of 1:2000. Protein detection was performed using the Bio-Rad
Clarity western ECL substrate (Bio-Rad). The ChemiDoc MP imager
and Image Lab software (Bio-Rad) were used to validate western blot-
ting data via total protein normalization in conjunction with house-
keeping proteins (β-tubulin).
2.6. Immunoﬂuorescence
Cells were grown on cell culture chamber slides, and ﬁxed in 1.5%
paraformaldehyde for 15 min. Cells were permeabilized with 0.1% Tri-
ton X-100 for 15 min and blocked with 2% BSA for 45 min. GLUD2 pri-
mary antibody was diluted 1:250 and incubated for 60 min at RT.
Phycoerythrin conjugated secondary antibody (P9287, Sigma Aldrich)
was diluted 1:20 and incubated for 30 min. Cells were counterstained
with Hoechst (Thermo Fisher Scientiﬁc) and visualized using the
inverted microscope CARL ZEISS Axio Observer 3 Z1FLMot (Zeiss).
2.7. Glutamate dehydrogenase activity
Intracellular glutamate dehydrogenase activity was measured by
using the GDHActivity Assay Kit (Sigma-Aldrich) according to theman-
ufacturer's protocol. The activity of glutamate dehydrogenase was
assayed photometrically (absorbance at 450 nm) following glutamate
consumption by GDH generatingNADH,which reacts with a probe gen-
erating a colorimetric product proportional to the GDH activity present.
After the addition of the Master Reaction Mix the plate was incubated
for 3 min at 37 °C degrees and the ﬁrst measurement was taken. Then,
every 10 min the absorbance at 450 nm was measured up to 60 min.
The resultswere visualized as generated NADHnanomoles perminutes,
normalized on the total protein concentration of each sample (Bradford
Reagent assay, Sigma-Aldrich). The experiment was performed in
triplicate.
2.8. Cell viability assay
Cell viability was determined using theWST1 assay (Clontech Labo-
ratories, Mountain View, CA, USA). A total of 5000 cells per well were
seeded in a 96-well plate format. At the time of seeding (T0) and after
24 h (T1), 48 h (T2) and 72 h (T3), theWST1 reagentwas added and in-
cubated for a further 60 min before reading the plate. Each assay was
conducted in triplicate. The quantity of formazan dye is directly related
to the number of metabolically active cells, and was quantiﬁed by mea-
suring the absorbance at 450 nm in a multiwell plate reader (Tecan,
Mannedorf, Switzerland). OD values at 24 h (T1), 48 h (T2) and 72 h
(T3) were normalized to T0.
2.9. Clonogenic survival assay
Cellswere seeded at 500 cells/well in 6-well plates and incubated for
2weeks. Cells were ﬁxedwith 70% ethanol and stainedwith 0.01% crys-
tal violet for 30min. Themean± SD number of colonies with N50 μm inplays a critical role in glioblastoma progression, EBioMedicine (2018),
4 S. Franceschi et al. / EBioMedicine xxx (xxxx) xxx–xxxdiameter was counted under a microscope in ﬁve non-overlapping
ﬁelds in three independent experiments.
2.10. Wound healing assay
Cells were plated in Culture-Insert 2 Well in μ-Dish 35 mm (IBIDI,
Martinsried, Germany) until cells were conﬂuent or nearly conﬂuent
(N90%). After the removal of the insert, cell migration in the wound
area was observed and digitally photographed. Wound healing was
measured on the images by using the free, open-source software ImageJ
[36] and the % of closure was calculated at each time (T0-T3, 0–72 h) as
the area to be healed divided the area of the original wound * 100. Rel-
ative invasion ability of pIRES-GLUD2 and pIRES Vector transfected cells
was measured by counting GFP signal (transfected cells) into the
wound. Experiments were performed in triplicate.
2.11. Transwell assay
Cell invasion was assessed using 24-well inserts (Sarstedt,
Nuembrecht, Germany) with 5-μm pores according to manufacturer's
instructions. In brief, 1 × 105 cells were seeded into the upper chamber
with 1% FBS medium and were allowed to invade the lower reservoir,
containing 10% FBS, at 37 °C for 24 h. Non-invading cells in the upper
surface of the ﬁlters were removed using a cotton swab. The remaining
cells were ﬁxed in 70% ethanol and stained with 0.01% crystal violet for
30 min. Cells that passed through the membrane were counted in ﬁve
visual ﬁelds as migrated cells. The experiment was performed in
triplicate.
2.12. Cell-cycle analysis
Approximately 1×106 cellswereﬁxed in 70%ethanol for 30min at 4
°C. The cells were then labeled with 25μg/ml of propidium iodide
(Sigma Aldrich), 1 mg/ml RNase A (Sigma Aldrich), 0,1% v/v of Triton
X-100 (Sigma Aldrich) and incubated 30 min in the dark at 4 °C. The
percentage of cells in different phases of the cell cycle was measured
by ﬂow cytometry using CyFlow1 Cube 8 Sorter Flow Cytometer
(Sysmex Partec, Gorlitz, Germany). Data analysis was performed using
FCS express 4 software (BD Bioscience San Jose, CA). The experiment
was performed in triplicate.
2.13. Mitochondrial respiration and glycolysis analysis
Cell mitochondrial function was evaluated by using the Seahorse
XFp Cell Mito Stress Test Kit on the Seahorse XFp Analyzer (Agilent
Technologies, Santa Clara, CA). Cells were seeded at 20,000 cells per
well into XFp well cell culture plates and incubated overnight at 37 °C
in a 5% CO2 humidiﬁed atmosphere in Seahorse XF Base Medium
(Agilent Technologies) with 1 mM pyruvate, 2 mM glutamine, and
10 mM glucose. Cartridge compounds were loaded in order to have as
ﬁnal concentration 1 μM Oligomycin, 1 μM FCCP and 0.5 μM Rotenone/
antimycin A. Data were analyzed and visualized using Wave 2.3.0 soft-
ware (Agilent Technologies) and values of OCR and ECARwere normal-
ized to the total protein levels (Bradford Reagent assay, Sigma-Aldrich)
in each well. The experiment was performed in three replicates.
2.14. Oxidative stress
To assess oxidative stress/reactive oxygen species (ROS), cells were
transfected with GLUD2 overexpression vector and silencing siRNA
and relative controls for two days in a 96 well plate. CellROX Green re-
agent was added at ﬁnal concentration of 5 uM to the cells and incubate
for 30min at 37 °C. Mediumwas removed and cells were washed three
times with PBS. The quantity of oxidative stress was quantiﬁed bymea-
suring the ﬂuorescence at an excitation/emission wavelength of 485/
535 nm in a multiwell plate reader (Tecan). The experiment wasPlease cite this article as: Franceschi S, et al, Mitochondrial enzyme GLUD2
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sured in four multiple reads.
2.15. Zebraﬁsh husbandry
Danio rerio (AB strain)was raised and bred at a temperature of 28 °C
with a photoperiod of 14 h light/10 h dark. Animal care was performed
in strict accordance with protocols approved by the Italian Ministry of
Public Health and the University of Pisa Ethical Committee (authoriza-
tion 99/2012-A, 19.04.2012), in compliance with EU legislation (Direc-
tive 2010/63/EU). Zebraﬁsh embryos were obtained by natural
spawning, staged according to the hours post fertilization [37] and
raised at 28 °C in 1× E3 medium (5.0 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, 0.33 mMMgSO4, 0.1% methylene blue) in Petri dishes.
2.16. Zebraﬁsh embryos experimental plan
To determine the zebraﬁsh embryos number to analyze in each ex-
perimental replicate we followed the indication reported in Busquet
et al., 2014 [38]. The authors reported zebraﬁsh embryo experiments re-
sults replicated in at least 3 independent laboratories suggesting that
the use of 20 embryos per treatment should be maintained to ensure
the accuracy of the experimental test. In our experiments, we processed
20–30 embryos per experimental group. Only properly developing em-
bryos between the 4- and 128-cell stages with an intact chorion were
used in our experiments as suggested in Busquet et al., 2014 [38].
2.17. Constructs generation and RNA microinjection
The open reading frame of GLUD2was subcloned into PCS2+ vector.
CappedmRNA encoding the full coding sequence of GLUD2was synthe-
sized using mMESSAGE mMACHINE™ SP6 transcription kit (Thermo
Fisher Scientiﬁc), following manufacturer's instructions. DNAse treat-
ment to remove template DNA was followed by phenol/chloroform ex-
traction and isopropanol precipitation, according to the kit procedures.
A capped mRNA encoding the full coding sequence of an enhanced
green ﬂuorescent protein (eGFP) reporter was also produced as de-
scribed above.
To perform gene gain of function experiments, GLUD2 cappedmRNA
was injected into the yolk sac of one-cell stage embryos (~200 pg per
embryo). 200 pg of eGFP capped RNAwere co-injected to verify success-
ful injections using a ﬂuorescence stereomicroscope.
For the selection of the correctly injected embryos we performed a
double check procedure with two different operators in order to mini-
mize any possible human bias in the embryo selection.
In all experiments, GLUD2-injected embryos were compared with
embryos injected with the only eGFP capped mRNA at the same devel-
opmental stage and cultured in the same conditions (same medium,
temperature, same incubator etc.) as a control.
Microinjections were performed using a FemtoJet microinjector
(Eppendorf).
2.18. Whole-Mount in situ hybridization
Zebraﬁsh embryos were manually dechorionated, ﬁxed in 4% para-
formaldehyde at the desired developmental stages and stored in meth-
anol at−20 °C. In situ hybridization was then performed as previously
described [39]. Digoxigenin-UTP labeled antisense RNAprobes to detect
pcna, gfap, slc1a3a, slc1a2b and cyclin D1 transcripts were generated via
in-vitro transcription according to the manufacturer's instructions
(Roche). The enzymes used for plasmids linearization and polymerases
for probes transcription are indicated: pcna (NotI, T7), gfap (SalI, SP6),
slc1a3a (BamHI, SP6), slc1a2b (EcoRV, T7), cyclin D1 (SpeI, T7). The
color reaction was carried out using the BM Purple substrate (Roche).
After color development, embryos were post-ﬁxed and bleached
under light to remove the pigment.plays a critical role in glioblastoma progression, EBioMedicine (2018),
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(gfap, slc1a3a). Pcna construct was generated as described in Baumgart
et al., 201439.2.19. Statistical analysis
All results are presented as mean± SD of at least three independent
experiments. For qRT-PCR experiments, graphs are representative of
three independent experiments with three technical replicates each.
Data were statistically analyzed applying student's t-test and visualized
using GraphPad Prism software (GraphPad Software, La Jolla, CA). Dif-
ferenceswere considered statistically signiﬁcantwhen p b 0.05 and rep-
resented as: *p b 0.05, **p b 0.01 and ***p b 0.001.3. Results
3.1. GLUD2 expression is associated with GBM prognosis and histopatho-
logical classiﬁcation
3.1.1. RNA-Seq
We previously used whole-transcriptome RNA sequencing [17] to
analyze 13 newly diagnosed cases of primary FFPE (formalin-ﬁxed
and parafﬁn-embedded) GBM, speciﬁcally selected for different length
of recurrence-free survival time (RFS). We deﬁned three groups: the
short-term group (S) with RFS b 6 months (n= 6), the medium term
group (M) with 16 b RFS b 23 months (n = 3) and the long-term
group (L) with RFS N 25 months (n = 4). Here, we performed a func-
tional enrichment analysis of the identiﬁed transcripts, ﬁnding statisti-
cally signiﬁcant differences in glutamate metabolism genes
(Supplementary Table S1). In particular, GLUD2 mRNA expression
means in the two extreme groups, S and L RFS GBM patients, were re-
spectively 10.49 and 143.05 with a fold change of 13.64, and a p-value
of 0.05 (Fig. 1a). Moreover, immunohistochemical analysis revealed
that the protein expression of GLUD2 detected in long RFS GBM tissues
was higher than that in short GBM (Fig. 1b).Fig. 1. GLUD2mRNA expression is related to recurrence free survival, prognosis, and histopath
patients with short RFS (b6 months) and long RFS (N25 months) from NGS analysis. (b) Im
(c) GLUD2mRNA expression in GBM patients with long survival (N104 weeks) and short surv
and WHO grade IV gliomas from GSE4271 dataset. (e) GLUD2 mRNA expression associatio
GSE4271 dataset. Data are presented as mean ± SD and differences were considered statistica
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From the GEO dataset we retrieved seventy-seven samples from
newly diagnosed cases of high-grade gliomas, which were proﬁled via
microarray analysis, to identify changes in GLUD2 mRNA expression
that relates to both survival and disease progression (Gene Expression
Omnibus dataset accession number: GSE4271, http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE4271).
We divided patients' cohort into two groups, depending on their
clinical outcome: overall survival (OS) b2 years (OS b 103 weeks)
and OS N 2 years (OS N 104 weeks). The longer survival group is de-
ﬁned by higher expression levels of GLUD2 (Fig. 1c; p = 0.0016).
Then we associated GLUD2 expression levels to the World Health Or-
ganization (WHO) classiﬁcation system of glioma grading. GLUD2 re-
sulted more expressed in grade III glioma tumors, compared to the
most aggressive form of glioma, GBM grade IV (Fig. 1d; p b 0.0001).
Finally, based on the molecular sub-classiﬁcation of high-grade astro-
cytoma, reported on the literature [18], we evaluated GLUD2 expres-
sion levels into the proneural, proliferative and mesenchymal classes.
Among these three groups, the proneural group, associated with the
most favorable outcome, was characterized by higher levels of
GLUD2 (Fig. 1e; p b 0.0001).3.2. Two human GBM cell lines with different GLUD2 expression levels
reveal distinct proliferation rate and colony formation capacity
3.2.1. GLUD2 molecular status in human Gbm cell lines
We selected two GBM human cell lines, T98G and U118, to investi-
gate GLUD2 expression level and enzyme activity. U118 cells had higher
levels of both GLUD2 mRNA (Supplementary Fig. S1a; p= 0.0009) and
protein (Supplementary Fig. S1b–c) than T98G cells. Moreover, gluta-
mate dehydrogenase activity, in the direction of oxidative deamination
of glutamate, showed higher enzymatic activity in U118 than T98G cells
(Supplementary Fig. S1d; p b 0.0001). Thewhole geneGLUD2 (including
promoter region) of both cell lines were sequenced and no mutations
were identiﬁed. Moreover, mutations in codon 132 of IDH1 and codons
140 or 172 of IDH2 have not been identiﬁed.ological classiﬁcation in high-grade glioma patients. (a) GLUD2mRNA expression in GBM
munohistochemical stain of GLUD2 protein in GBM patients with short and long RFS.
ival (b103 weeks) from GSE4271 dataset. (d) GLUD2mRNA expression in WHO grade III
n with molecular sub classiﬁcation in high-grade gliomas and relative prognosis from
lly signiﬁcant when p b 0.05 and represented as: *p b 0.05, **p b 0.01 and ***p b 0.001.
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Once established statistically signiﬁcant differences in GLUD2 ex-
pression level and enzyme activity, we performed in-vitro cell prolifera-
tion and tumorigenic assays to investigate U118 and T98G cell behavior
dissimilarities.
Cell proliferation rate in T98G at four different time points, T0, T1
(24 h), T2 (48 h) and T3 (72 h), as shown in Supplementary Fig. S1e,
was higher than in U118, (p= 0.0128 T1, 0.0003 T2 and 0.0015 T3).
Colony-forming assay revealed a higher colonies number in T98G
cells compared to U118 cells (Supplementary Fig. S1f; p b 0.0001).
Therefore, GLUD2 lower expression was associated with enhancing
cell proliferation signal and higher colony formation ability.
3.3. GLUD2 overexpression decreases proliferation, migration, invasion
and colony formation abilities of GBM Cells
3.3.1. GLUD2 overexpression in human GBM cell lines
We evaluated the effects of GLUD2 overexpression on T98G cells, se-
lected due to lowerGLUD2 expression. T98G cells were transfectedwith
GLUD2-IRES-GFP plasmid system (pIRES-GLUD2). As a control, we
transfected the same cells with the empty vector (pIRES Vector). After
transfection, GLUD2 mRNA expression (Supplementary Fig. S2a; p b
0.0001), GLUD2 protein expression (Supplementary Fig. S2b–c) and
GLUD2 enzymatic activity (Supplementary Fig. S2d; p b 0.0001) were
increased in pIRES-GLUD2 cells compared to cells with empty vector.
3.3.2. Cell functional in-vitro studies on GLUD2 overexpressing T98G cells
We used a WST-1 cell proliferation assay to determine the effect of
GLUD2 overexpression in T98G cells at four different time points, T0,
T1 (24 h), T2 (48 h) and T3 (72 h). We found that overexpression ofFig. 2. GLUD2 overexpression decreases GBM cells proliferation, migration, invasion and colo
GLUD2) and control (pIRES Vector) at the time of seeding (T0) and after 24 h (T1), 48 h (T2) a
GLUD2) and control (pIRES Vector) and (c) their relative wound invasion ability. (d) Transwe
(pIRES Vector). Cells that passed through the membrane were counted in ﬁve visual ﬁelds
(pIRES-GLUD2) and control (pIRES Vector). Colonies were counted in ﬁve non-overlapping
signiﬁcant when p b 0.05 and represented as: *p b 0.05, **p b 0.01 and ***p b 0.001.
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We investigated, by wound healing assay, the effect of GLUD2 over-
expression on migration in T98G cells at three different time points, T0,
T1 (24 h), T2 (48 h) and T3 (72 h). The wound healing assay results
showed thatGLUD2 overexpression suppressed thewound healing abil-
ity compared with empty vector transfected cells (Fig. 2b; p =
0.0087 T1, 0.0213 T2, 0.0058 T3). We then analyzed wound healing
assay only looking at the GFP signal, to compare migration capacity of
transfected cells in relation to their different GLUD2 expression levels.
We observed that pIRES-GLUD2 cells were almost unable to move into
the wound whereas control cells transfected with vector alone (pIRES
Vector) invaded the wound area (Fig. 2c; p = 0.0250). To determine
the effect ofGLUD2 overexpression on T98G cell invasion,we performed
a transwell invasion assay. The number of migrating cells was distinctly
lower in pIRES-GLUD2 cells than in control cells (Fig. 2d; p b 0.0001).
Colony formation assayswere performed in order to evaluateGLUD2
overexpression effect on the clonogenic survival.GLUD2 overexpression
reduced the T98G colony formation ability (Fig. 2e; p= 0.0045).
3.4. GLUD2 silencing increases proliferation, migration, invasion and colony
formation abilities of GBM cells
3.4.1. GLUD2 silencing in human GBM cell lines
We examined the effects of GLUD2 silencing selecting U118 cells due
to their higher GLUD2 expression. U118 cells were transfected with
GLUD2 siRNA system (siRNA GLUD2). As control, we transfected the
same cells with a non-targeting negative control siRNA (siRNA C+).
As shown in Supplementary Fig. S1, after transfection with
siRNA GLUD2, GLUD2 mRNA expression (Supplementary Fig. S1a;ny formation abilities. (a) Cell viability of T98G cells after GLUD2 overexpression (pIRES-
nd 72 h (T3). (b) Wound healing assay of T98G cells after GLUD2 overexpression (pIRES-
ll migration assay of T98G cells after GLUD2 overexpression (pIRES-GLUD2) and control
as migrated cells. (e) Colony formation assay of T98G cells after GLUD2 overexpression
ﬁelds. Data are presented as mean ± SD and differences were considered statistically
plays a critical role in glioblastoma progression, EBioMedicine (2018),
S. Franceschi et al. / EBioMedicine xxx (xxxx) xxx–xxxp b 0.0001), GLUD2 protein expression (Supplementary Fig. S1b and
c) and GLUD2 enzymatic activity (Supplementary Fig. S1d; p b 0.0001)
were decreased compared to control cells.
3.4.2. Cell functional in-vitro studies on GLUD2 silenced U118 cells
We used a WST-1 cell proliferation assay to determine the effect of
GLUD2 silencing in U118 cells. We found that silencing of GLUD2 en-
hances cell proliferation (Fig. 3a; p b 0.0001 T1, p b 0.0001 T2, p =
0.0002 T3).
We investigated the effect of GLUD2 silencing on migration in U118
cells by wound healing at three different time points, T0, T1 (24 h), T2
(48 h) and T3 (72 h). The wound healing assay results showed that
GLUD2 silencing improved the wound healing ability compared to con-
trol siRNA transfected cells (Fig. 3b; p = 0.0010 T1, 0.0272 T2,Fig. 3.GLUD2 silencing increases GBMcells proliferation,migration, invasion and colony formati
(siRNA C+) at the time of seeding (T0) and after 24 h (T1), 48 h (T2) and 72 h (T3). (b)Wound
(c) Transwell migration assay of U118 cells after GLUD2 silencing (siRNA GLUD2) and control (
migrated cells. (d) Colony formation assay of U118 cells after GLUD2 silencing (siRNA GLUD2)
presented as mean ± SD and differences were considered statistically signiﬁcant when p b 0.0
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vasion,we performed a transwell invasion assay. The number ofmigrat-
ing cells was distinctly higher in siRNA GLUD2 cells than in control cells
(Fig. 3c; p b 0.0001).
Colony formation assayswere performed in order to evaluateGLUD2
silencing effect on the clonogenic survival. GLUD2 silencing increased
the U118 colony formation ability (Fig. 3d; p b 0.0001).
3.5. GLUD2 expression levels inﬂuence G1/S transition regulating cyclins D1
and E in human GBM cells
We studied by ﬂow cytometry the effect of both GLUD2 overexpres-
sion and silencing on T98G and U118 cell cycle. GLUD2 overexpression
in T98G cells showed a signiﬁcant increase in G0/G1 phase and aon abilities. (a) Cell viability of U118 cells afterGLUD2 silencing (siRNAGLUD2) and control
healing assay of U118 cells after GLUD2 silencing (siRNAGLUD2) and control (siRNA C+).
siRNA C+). Cells that passed through the membrane were counted in ﬁve visual ﬁelds as
and control (siRNA C+). Colonies were counted in ﬁve non-overlapping ﬁelds. Data are
5 and represented as: *p b 0.05, **p b 0.01 and ***p b 0.001.
plays a critical role in glioblastoma progression, EBioMedicine (2018),
Fig. 4. GLUD2 overexpression and silencing in GBM cells modulate the expression of cyclin D1 and cyclin E, inﬂuencing cell cycle phases and affect mitochondrial function and ROS
production. (a) Cell cycle distribution in T98G GLUD2 overexpressed cells (pIRES-GLUD2) and U118 GLUD2 silenced cells (siRNA GLUD2) compared to relative control cells. (b) Cyclin
D1 and Cyclin EmRNA expression in GLUD2 overexpressed cells (pIRES-GLUD2) and GLUD2 silenced cells (siRNA GLUD2) compared to relative control cells. (c) Oxygen consumption
rate (OCR) of T98G control cells (pIRES Vector), T98G GLUD2 overexpressed cells (pIRES-GLUD2), U118 control cells (siRNA C+) and U118 GLUD2 silenced cells (siRNA GLUD2) in
Seahorse XFp Cell Mito Stress Test. (d) Basal and maximal respiration, non-mitochondrial respiration, H+ (Proton) leak, ATP-linked respiration, spare respiratory capacity and
coupling using modulators of cellular respiration. (e) ROS levels of T98G GLUD2 overexpressed cells (pIRES-GLUD2), U118 GLUD2 silenced cells (siRNA GLUD2) and relative controls
quantiﬁed by measuring the ﬂuorescence at an excitation/emission wavelength of 485/535 after CellROX Green probe incubation. Data are presented as mean ± SD and differences
were considered statistically signiﬁcant when p b 0.05 and represented as: *p b 0.05, **p b 0.01 and ***p b 0.001. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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to control cells (Fig. 4a; p b 0.0001 G0/G1 and p= 0.0008 S). GLUD2 si-
lencing in U118 cells with siRNA did not lead to a statistically signiﬁcant
change in the cell cycle (Fig. 4a).
We then evaluated the mRNA expression of G1 phase cell cycle reg-
ulators, cyclin D1 and cyclin E. GLUD2 overexpression in T98G cells is
characterized by cyclin D1 and cyclin E downregulation (Fig. 4b; p =
0.0083 D1 and p = 0.0003 E). GLUD2 silencing in U118 cells showed
an overexpression of both cyclin D1 and cyclin E (Fig. 4b; p = 0.0124
D1 and p= 0.0336 E).
3.6. Changes in GLUD2 expression levels determine alterations of mitochon-
drial functions in human GBM cells
To obtain insight into mitochondria functional differences be-
tween GLUD2 overexpressed and silenced cells, we analyzed mito-
chondrial function and metabolic phenotype by quantifying oxygen
consumption rate (OCR) with Seahorse XFp extracellular ﬂux
analyzer.
We examined GLUD2 overexpression and silencing effects on
basal respiration, ATP-linked respiration, H+ (Proton) leak, maximal
respiration, spare respiratory capacity, and non-mitochondrial respi-
ration, using the Seahorse XFp Cell Mito Stress Test Kit (Supplemen-
tary Fig. S3). GLUD2 overexpression in T98G cells led to a statistically
signiﬁcant increase in the basal levels of mitochondrial respiration (pPlease cite this article as: Franceschi S, et al, Mitochondrial enzyme GLUD2
https://doi.org/10.1016/j.ebiom.2018.10.008= 0.0015) and maximal respiration (p b 0.0001) compared to empty
vector control (Fig. 4c–d). Instead, GLUD2 silencing in U118 caused
a statistically signiﬁcant reduction of basal mitochondrial respiration
(p = 0.0416), whereas no statistically signiﬁcant differences were
observed in the maximal respiration compared to the respective con-
trol (Fig. 4c–d). Non-mitochondrial respiration was also statistically
increased in T98G cells with GLUD2 overexpression (p = 0.0004)
and decreased in U118 cells with GLUD2 silencing (p = 0.0057) com-
pared to respective controls (Fig. 4c–d). Despite proton leak and ATP
production were increased in T98G cells with GLUD2 overexpression
and decreased in U118 cells with GLUD2 silencing, compared to the
respective controls, differences were not statistically signiﬁcant
(Fig. 4c–d). Spare respiratory capacity was signiﬁcantly increased in
GLUD2 overexpressed T98G cells (p = 0.0006) whereas no signiﬁcant
differences were observed in the spare respiratory capacity in GLUD2
silenced U118 cells. No statistically signiﬁcant differences, in couple
efﬁciency, were observed in both GLUD2 overexpressed T98G cells
and GLUD2 silenced U118 cells compared to their respective controls
(Fig. 4c–d).
To evaluate reactive oxygen species (ROS) levels, GLUD2
overexpressed cells, GLUD2 silenced cells and relative controls were
stained with CellROX Green reagent, followed by ﬂuorescence quantiﬁ-
cation of oxidative stress. We found higher levels of ROS in the GLUD2
overexpressed cells (p b 0.0001) and lower levels in the GLUD2 silenced
cells (p b 0.0001) compared to controls (Fig. 4e).plays a critical role in glioblastoma progression, EBioMedicine (2018),
Fig. 5. GLUD2 overexpression affects cell proliferation in zebraﬁsh embryos. (a) Schematic mRNA microinjection procedure into the yolk sac of a one-cell stage zebraﬁsh embryo.
(b) Zebraﬁsh embryo injected with eGFP mRNA at 24 hpf. (c) Control immunohistochemical staining of GLUD2 protein on 24 hpf zebraﬁsh embryos injected with eGFP mRNA
(control) or GLUD2 and eGFPmRNAs (GLUD2), showing GLUD2 expression in GLUD2-injected embryos. (d) Immunohistochemical staining of pH 3 (phosphohistone H3) on 24 and 48
hpf embryos injectedwith only eGFPor eGFP andGLUD2mRNAs. (e)Number of pH3-positive cellswas counted in thehindbrain area (black square ind) of 48hpf embryos; n, total number
of analyzed embryos, N, number of independent experiments. (f)Wholemount in situ hybridization on bothGLUD2-injected and control embryos at 48 and 72 hpf, showing a reduction of
pcna expression in GLUD2-injected embryos; arrowheads indicate the proliferative region of the optic tectum. 72 hpf embryos are shown in dorsal and lateral view. (g) Percentage of
GLUD2-injected and control embryoswith reduced pcna expression; n, total number of analyzed embryos, N, number of independent experiments. (h) qRT-PCRanalysis of pcna expression
inGLUD2-injected and control embryos at 48 hpf; n, total number of analyzed embryos, N, number of independent experiments. (i)Wholemount in situ hybridization on 48 hpf embryos,
showing a reduced cyclin D1 expression in GLUD2-injected embryos compared to controls; arrowheads indicate the proliferative region of the optic tectum. 48 hpf embryos are shown in
dorsal and lateral view. (j) Percentage of GLUD2-injected and control embryos with reduced cyclin D1 expression; n, total number of analyzed embryos, N, number of independent exper-
iments. (k) qRT-PCR analysis of cyclin D1 expression level in control and GLUD2-injected embryos; n, total number of analyzed embryos, N, number of independent experiments. Data are
presented as mean ± SD and differences were considered statistically signiﬁcant when p b 0.05 and represented as: *p b 0.05, **p b 0.01 and ***p b 0.001.
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The GLUD2 overexpression ability to reduce the proliferation rate of
GBM cell line T98Gwell correlates with the GLUD2 higher expression in
the long RFS group of patients. Nevertheless, the tissue culture condition
could not entirely recapitulate the in-vivo condition in which multiple
signaling factors and cell-cell interactions could inﬂuence cell behavior
and metabolism. We therefore decided to test the function of GLUD2
in an in-vivo system to verify the GLUD2 overexpression inﬂuence on
cell proliferation in the central nervous system. We chose Danio rerio
(zebraﬁsh) as experimental model as it is a well accepted tool in bio-
medical research, including brain cancer research [19,20], allowing us
to overexpress the human GLUD2 and to evaluate its effect on neurons
and glial cells behavior in the developing brain.
Embryos were injected with GLUD2 and eGFP mRNAs at one-cell
stage (Fig. 5a). As a control, a group of embryos was injected with
only eGFPmRNA. Effectively injected embryos were selected detecting
eGFP expression by ﬂuorescence stereomicroscope (Fig. 5b).
We ﬁrst assessed the ability of zebraﬁsh embryos to express the
human GLUD2 protein; GLUD2 expression was observed in GLUD2-
injected embryos by immunohistochemistry, but not in the control
group (Fig. 5c).3.7.1. GLUD2 overexpression affects cell proliferation in zebraﬁsh embryos
We used a phosphohistone H3 antibody to analyze cell proliferation
in the central nervous system and, in particular, to visualize cells during
M phase of the cell cycle in zebraﬁsh embryos at two different develop-
mental stages, 24 hpf (hours post fertilization) and 48 hpf (Fig. 5d). The
result revealed a decreased number of proliferating cells in GLUD2-
injected embryos compared to controls. This observationwas conﬁrmedFig. 6. GLUD2 overexpression impairs glial cells formation, without affecting neurons develo
indicating a reduction of the expression of three different glial cell markers (slc1a3a, slc1a2b
injected and control embryos with decreased glial cell marker expression; n, total number of an
the reduced transcript level of gfap in GLUD2-injected embryos relative to control embr
(d) Immunohistochemical staining of HuD on 48 hpf embryos shown in dorsal and lateral vi
three independent experiments) revealing no visible differences in the expression of this postm
as mean ± SD and differences were considered statistically signiﬁcant when p b 0.05 and repr
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embryos at 48 hpf (Fig. 5e).
We then performed a whole mount in situ hybridization (WISH)
using an antisense RNA probe to detect pcna (proliferating cell nuclear
antigen) mRNA, which encodes a non-histone nuclear protein used as
amarker for cells in S phase. At 48hpf,GLUD2-injected embryos showed
reduced pcna transcript expression level compared to controls, that was
conﬁrmed by quantitative real-time RT-PCR (qRT-PCR) (Fig. 5f–h). At
later stages, 72 hpf, the effect became more pronounced highlighting a
severely reduced pcna gene expression clearly detectable in prolifera-
tive regions of the optic tectum of GLUD2-injected embryos (Fig. 5f, g).
These results suggested thatGLUD2overexpression could cause a reduc-
tion of cells in both S and M phases conﬁrming the results obtained in
T98G cells.
As in GBM cell line T98G overexpressing GLUD2 the reduced prolif-
eration correlateswith a reduction of cyclin D1 expression,we evaluated
cyclin D1mRNA level in GLUD2 overexpressing embryos both by in situ
hybridization and qRT-PCR (Fig. 5i–k). Cyclin D1WISH signal intensity
was strongly decreased in the tectal proliferative region of 48 hpf
GLUD2-injected embryos in comparison to controls (Fig. 5i, j) and was
found to be signiﬁcantly downregulated in GLUD2-injected embryos
also by qRT-PCR analysis (Fig. 5k).
3.7.2. GLUD2 overexpression impairs glial cells formation without affecting
neurons development
An altered glutamatemetabolism could affect not only glial cells ex-
pressing GLUD2 but also the nearby neurons survival. Zebraﬁsh model
allowed us to further investigate the effects of GLUD2 overexpression
on neural and glial development. We ﬁrst questioned whether this en-
zyme might have an inﬂuence on zebraﬁsh gliogenesis. We therefore
assessed the expression pattern of different glial markers by WISH onpment in zebraﬁsh embryos. (a) Whole mount in situ hybridization on 48 hpf embryos,
and gfap) in GLUD2-injected embryos compared to controls. (b) Percentage of GLUD2-
alyzed embryos, N, number of independent experiments. (c) qRT-PCR analysis conﬁrming
yos; n, total number of analyzed embryos, N, number of independent experiments.
ew (n = 84 for control embryos and n = 92 for GLUD2-injected embryos subdivided in
itotic neuronal marker between GLUD2-injected and control embryos. Data are presented
esented as: *p b 0.05, **p b 0.01 and ***p b 0.001.
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reduction of slc1a3a (Fig. 6a, b), an early glial marker encoding an excit-
atory amino acid transporter (EAAT) expressed at glutamatergic synap-
ses [21]. In addition, we analyzed the expression of slc1a2b (Fig. 6a, b),
an EAAT mainly present in a subset of glial cells [22], which was found
decreased in GLUD2-injected embryos compared to controls. To further
evaluatewhether the reduction of slc1a3awasdue to increased glial dif-
ferentiation or not, we examined the expression of a mature glial cells
marker, gfap, also used as an astrocytes marker [21]. Gfap downregula-
tion after GLUD2 mRNA injection was detected by WISH (Fig. 6a,
b) and conﬁrmed by qRT-PCR (Fig. 6c), suggesting an impairment of
gliogenesis caused by GLUD2 overexpression.
With the aim of investigating a potential effect ofGLUD2 overexpres-
sion on neurogenesis, we performed an immunohistochemical analysis
visualizing the postmitotic neuronal marker HuD distribution (Fig. 6d).
Compared to controls,GLUD2-injected embryos didn't display visible al-
terations of HuD expression pattern at 48 hpf, indicating that GLUD2
overexpression could affect glial cell development without impairing
neuronal differentiation and survival.4. Discussion
Glutamate dehydrogenase (GDH) is a mitochondrial enzyme that
catalyzes the reversible inter-conversion of glutamate to α-KG by
using NADP and/or NAD as cofactors. GDH in human exists in GLUD1
and GLUD2 gene-encoded isoforms (hGDH1 and hGDH2, respectively).
GLUD1 gene is located on 10q and is expressed widely, whereas
GLUD2 is an intronless gene located on the X chromosomewith expres-
sion speciﬁcity for nervous and testicular tissues [23,24]. In the brain,
GLUD2 expression is mainly associated with astrocytes [24,25] with a
substantial mitochondrial localization, representing up to 10% of the
matrix protein [10,25,26]. GLUD2 contributes to important cellular pro-
cesses, such as the Krebs cycle, ammonia homeostasis and energy pro-
duction [10,15,24,26,27]; however, its role in cell biology is still
incompletely understood [26]. GLUD2 has the ability to act on both di-
rections of the reaction depending on the availability of the substrate,
but in the cancer it is thought that it works mainly in the direction of
the oxidative deamination of glutamate and α-KG production [28].
GLUD2 initially emerged from our previous NGS analysis [17] con-
ducted on 13 GBM samples from patients with different recurrence
time (RFS). GLUD2 was overexpressed in the tumors of patients with
long RFS. We then interrogated the Gene Expression Omnibus dataset
in which 77 samples from newly diagnosed cases of high-grade gliomas
were proﬁled via microarray analysis. We found that GLUD2 overex-
pression was signiﬁcantly associated with increased overall survival
and lower glioma grading.
We then performed in-vitro functional studies on human GBM cells
evaluating cellular effect due to changes in GLUD2 expression levels.
In particular, we overexpressed and silenced GLUD2 in two different
cell lines, T98G and U118, respectively. GLUD2 overexpression led to a
signiﬁcant decrease in cell proliferation, invasion and migration capac-
ity and colony formation ability; at the same time, GLUD2 silencing
caused a statistically signiﬁcant increase in tumor aggressiveness and
tumorigenicity.
There is increasing evidence that glutamate oxidative deamination is
the predominant pathway for α-KG production and therefore its abun-
dance strictly depends on GLUD2 activity [16,29]. This also suggests an-
other possible explanation of decrease of proliferation following an
increase in the enzymatic activity of GLUD2 and vice versa. In fact,
when there is higher consumption of glutamate as a substrate, there is
higher attraction of glutamate from the outside towards the inside of
the cell and as a consequence, the extracellular glutamate decreases
with less effect on the promotion of cell proliferation through the acti-
vation of its receptors [30]. Other studies have observed that the in-
crease of glutamate uptake within the glioma cell, through thePlease cite this article as: Franceschi S, et al, Mitochondrial enzyme GLUD2
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[30,31].
Afterward, we investigated how GLUD2 expression levels could af-
fect the cell cycle phases and their regulation by checkpoints. Both cyclin
D1 and cyclin E expression levels are reduced after GLUD2 overexpres-
sion and this is reﬂected on the G0/G1 phase increase and S and G2/M
phase reduction. However, a variation of cell cycle phases is not appre-
ciable in GLUD2 silenced cells, although there is a signiﬁcant increase in
both cyclin D1 and cyclin E expression levels,. This is probably due to the
small difference in the increase of cyclin E in GLUD2 silenced cells com-
pared to control cells. The role of cyclin D1, in fact, is to advance the G1
phase and prepare cells for the S phase; whereas cyclin E is responsible
for G1-to-S-phase transition [32].
We also evaluated the consequences of GLUD2 expression levels
variation on mitochondrial function and metabolic phenotype, by mea-
suring oxygen consumption rate (OCR) after GLUD2 overexpression and
silencing. Statistically signiﬁcant effects, in both overexpression and si-
lencing of GLUD2 with opposite trends, were observed in the baseline
oxygen consumption and non-mitochondrial respiration. GLUD2 over-
expression seems, therefore, correlated with an increase in oxygen con-
sumption, which however does not translate into an increase in
oxidative phosphorylation, as there are no signiﬁcant differences in
the production of ATP. The fact that there are differences in non-
mitochondrial respiration has led us to investigate the production of re-
active oxygen species (ROS). We have indeed observed that GLUD2
overexpression increased the production of ROS and on the other
hand, after GLUD2 silencing, the production of ROS was decreased, as
expected. The effect of GLUD2 on ROS production, depending on its ex-
pression level, helped clarifying themechanisms bywhich altered levels
of GLUD2 expression can modify tumor progression and development.
The correlation between GLUD2 expression levels and ROS produc-
tion has already been described in the literature [27]. In particular, it
has been demonstrated that increased glutamate oxidation by an en-
hanced GLUD2 activation by the Ala445 variant in the regulatory do-
main, may improperly boost mitochondrial oxidative metabolism with
consequent increased ROS production [25]. This suggests that a signiﬁ-
cant gain in GLUD2 activity can cause severemitochondrial dysfunction,
as mitochondria fail to manage the large amounts of GLUD2 produced
α-KG. Moreover, it has also been described that GLUD2 NADPH genera-
tion affects ROS homeostasis trough NADPH oxidase activation and ROS
production [28]. Furthermore, an increase in ROS generation following
GLUD2 overexpression may also explain the resulting cell cycle block
in G0 / G1, since it has been shown that increased levels of ROS lead to
a decrease in cyclin D1/E expression and promote cell-cycle arrest
[33,34].
All these metabolic variations observed in-vitro could be differen-
tially regulated in-vivo by extracellular stimuli and cell–cell interactions
that give rise to a complex and integratedmodulation of cell behavior. In
order to test the possible effect of GLUD2 overexpression in-vivo we
took advantage of zebraﬁsh embryos in which we can easily alter
GLUD2 expression andmonitor cell cycle progression in the developing
central nervous system.Over the past years, zebraﬁsh has become an ef-
fective and alternative tool to the classical mouse model for studying
many human diseases including CNS pediatric to adult tumors [19,20].
However obvious evolutive divergences between ﬁshes and humans
have always to be taken into account. In this work we decided to use
the zebraﬁsh embryo just to evaluate GLUD2 gene function in a cellular
context in which all the metabolic pathways are active and the interac-
tion and exchanges between glia, neurons, hormones, neurotransmit-
ters and metabolites are orchestrated in a complex and dynamic
environment that is not reproducible in-vitro.
In GLUD2-overexpressing embryos we observed a reduced number
of mitotic cells in the developing brain that correlated with a decreased
level of cyclin D1 expression mirroring the data obtained in the T98G
human GBM cell line. These observations strongly corroborated the in-
vitro data adding important hints on the possible side effects of theplays a critical role in glioblastoma progression, EBioMedicine (2018),
12 S. Franceschi et al. / EBioMedicine xxx (xxxx) xxx–xxxGLUD2modulation. The in-vivo system, in fact, allowed us to verify how
glial cells overexpressing GLUD2 proceed in their developmental pro-
gram and how they can inﬂuence the behavior of the surrounding neu-
rons. In GLUD2 overexpressing embryos we observed a failure in the
generation of differentiated glial cells, probably due to a block of prolif-
eration of gliogenic precursors, but interestingly neurogenic precursors
seem not to be affected as post mitotic neurons developed normally.
This aspect could reﬂect the different metabolic activity of glial cells
and neurons and could be of great interest in a therapeutic perspective.
The possibility to enhance GLUD2 activity in GBM could result in a
blocked/reduced proliferation of glial cellswithout affecting the survival
of the surrounding neurons.
To the best of our knowledge, this is the ﬁrst work where GLUD2 is
considered as a key player in GBM progression. These observations
may provide a new target for therapeutic interventions in GBM to re-
duce tumor progression and aggressiveness. On this, however, there is
still much to learn about when and how tomanipulate glutamatemeta-
bolic system as a target and to further clarify the intracellular signaling
pathways associated with pathological states. In particular, preclinical
studies onmore complex animalmodels than zebraﬁsh, such asmurine,
will be necessary. This work could represent a starting point to deepen
the role of GLUD2 in GBM in-vivo and to design and test possible phar-
macological treatments. GLUD2 enzymatic activity could be increased
through the induction of an activating mutation, for example the
Ala445variant in the regulatory domain [25],with ahighly advancedge-
nome editing system such as CRISPR/Cas9. Alternatively, activation of
GLUD2 could be achieved by allosteric effectors, such as leucine [35], al-
though in this case the assessment of speciﬁcity is extremely important.
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